Nova Mentis Life Science Corp. has formed a tactical partnership with KGK Science Inc. to develop its psilocybin drug portfolio in Canada. Both Companies plan to jointly submit the Health Canada clinical trial application.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.015 CAD | 0.00% | -25.00% | -25.00% |
1st Jan change | Capi. | |
---|---|---|
-25.00% | 1.62M | |
+21.85% | 46.93B | |
+37.63% | 39.08B | |
-8.05% | 38.48B | |
+29.04% | 31.01B | |
-13.75% | 26.14B | |
+10.65% | 25.88B | |
+38.43% | 12.53B | |
-6.92% | 11.36B | |
-12.29% | 10.65B |
- Stock Market
- Equities
- NOVA Stock
- News Nova Mentis Life Science Corp.
- Nova Mentis Life Science Corp. Forms A Tactical Partnership with KGK Science Inc. to Develop Its Psilocybin Drug Portfolio in Canada